AN2 Therapeutics director granted 20,400 stock options

AN2 Therapeutics director Aziz Kabeer received a grant of 20,400 stock options (right to buy) on February 20, 2026.

Accepted by SEC EDGAR 02/23/2026 - 04:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AN2 Therapeutics director Aziz Kabeer received a grant of 20,400 stock options (right to buy) on February 20, 2026. The options have an exercise price of $0.00 per share and are held directly.

The option shares are scheduled to vest on February 20, 2027, provided Kabeer continues to provide service to the company through that date. After this grant, he holds 20,400 derivative securities related to the company’s stock options.

Insider Trade Summary

Grant/Award: 20,400 shares

Grant/Award 1 txn

Insider Aziz Kabeer

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,400	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,400 contracts (Direct)

Footnotes (1)

1. F1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AN2 Therapeutics (ANTX) report for Aziz Kabeer?

AN2 Therapeutics reported that director Aziz Kabeer received a grant of 20,400 stock options on February 20, 2026. These options carry an exercise price of $0.00 per share and are held directly, increasing his total derivative securities holdings to 20,400 options.

How many stock options were granted to AN2 Therapeutics (ANTX) director Aziz Kabeer?

Aziz Kabeer was granted 20,400 stock options labeled as a “Stock Option (Right to Buy).” This award was reported with a transaction code A, indicating a grant, award, or other acquisition, and reflects his entire reported derivative position following the transaction.

When do Aziz Kabeer’s AN2 Therapeutics (ANTX) stock options vest?

The option shares granted to Aziz Kabeer are scheduled to vest on February 20, 2027. Vesting is conditioned on his continuous service to AN2 Therapeutics through that date, meaning he must remain in service until then for the options to become exercisable.

What does the vesting condition mean for AN2 Therapeutics (ANTX) director stock options?

The vesting condition requires Aziz Kabeer to provide continuous service to AN2 Therapeutics until February 20, 2027. If he meets this requirement, all 20,400 option shares will vest on that date, aligning the award with ongoing board or service commitments.

How is the ownership of the AN2 Therapeutics (ANTX) stock options characterized for Aziz Kabeer?

The Form 4 characterizes Aziz Kabeer’s ownership of the 20,400 stock options as direct. The filing does not attribute the options to any trust, LLC, or other entity, indicating the award is held in his own name for reporting purposes.

What transaction code was used for the AN2 Therapeutics (ANTX) option grant to Aziz Kabeer?

The transaction used code A, which indicates a grant, award, or other acquisition of derivative securities. This code reflects that the 20,400 stock options were awarded to Aziz Kabeer rather than purchased or sold on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aziz Kabeer

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.04	02/20/2026		A		20,400		(1)	02/19/2036	Common Stock	20,400	$0	20,400	D

Explanation of Responses:

1. The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date.

	/s/ Lucy Day, Attorney-in-Fact for Kabeer Aziz	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.